ObjectiveTo assess the effect of high-dose vitamin D in patients with painful diabetic neuropathy.MethodsA single intramuscular dose of 600 000 IU vitamin D was administered, and the effects on metabolic parameters and neuropathic pain assessed over 20 weeks.Results143 participants with predominantly type 2 diabetes, aged 52.31±11.48 years, with a Douleur Neuropathique 4 (DN4) score (3.0±1.8), total McGill pain score (21.2±14.9), and Short Form McGill Pain Questionnaire (SFMPQ) score (2.1±0.9), were enrolled. The baseline 25-hydroxyvitamin D (25(OH)D) level was 31.7±23.3 ng/mL and 58 (40.5%) patients showed evidence of vitamin D deficiency (25(OH)D<20 ng/mL). Intramuscular administration of vitamin D resulted in a significant increase in 25(OH)D (46.2±10.2 ng/mL, p<0.0001) and a reduction in positive symptoms on the DN4 (p<0.0001), total pain score (p<0.0001), and SFMPQ (p<0.0001).ConclusionsTreatment with a single intramuscular dose of 600 000 IU of vitamin D in patients with painful diabetic neuropathy is associated with a significant decrease in the symptoms of painful diabetic neuropathy.Trial registration numberBIDE-12/2014.
Oral route of administration gets the highest priority for the delivery of drug as well as better patient compliance. Floating tablet is selected for achieving a prolonged and predictable drug delivery profile in the gastrointestinal tract to control the gastric residence time using a gastro retentive dosage forms that will provide as with new and important therapeutic options. The design of oral controlled drug delivery systems is aimed primarily to achieve more predictable and increased bioavailability. However, this system have several physiological difficulties, such as inability to restrain and localized oral control drug delivery systems within desired reasons of the gastro intestinal tract and the highly variable nature of the gastric emptying process. Gastric emptying time in humans, which is normally 2-3 hours through the main absorption area (stomach or upper part of intestine), can result in incomplete drug release from oral controlled drug delivery system leading to diminished efficacy of an administered dose. Intimate contact of oral controlled drug delivery system with the absorbing membrane has the potential to maximize drug absorption and also influence the rate of drug absorption .These consideration have lead to the development of oral controlled gastroretentive dosage forms possessing gastric retention capabilities . Pantoprazole floating tablets is used to treat and prevent bacterial infections in the stomach and intestines. Keywords: Bioadhesive Floating Matrix, Pantoprazole, Polymers, sodium bi carbonate and citric acid, in vitro drug release studies.
Objective: To observe the adherence of Healthcare Professionals to American Diabetes Association (ADA) 2004 guidelines for the care of patients with type 2 diabetes at Peripheral Diabetes Clinics (PDCs) in Karachi, Pakistan. Methodology: The study was conducted using a retrospective medical chart review of patients with type 2 diabetes at four PDCs in four townships of Karachi district from January 2005 to December 2006. Entire medical records of patients were evaluated for the evidence of documentation of testing and treatment. Results: Medical records of 691 patients (332 males and 359 females) with type 2 diabetes were reviewed. Mean age of the patients was 50.79 ± 10.75 years. Deficiencies were observed in most areas of diabetes care. Blood pressure was documented in 85.81% patients, whereas, serum creatinine, HbA1c and lipid profile were noted in 56%, 44.57% and 40.08% of the patients respectively. Similarly, lower leg examination was registered in 44% patients, while in 30.53% of the patients fundoscopic examination was recorded. Co-morbid conditions like hypertension and hyperlipidemia were documented in 92.7% and 84.6% patients respectively. HbA1c < 7% was achieved by 59.04% patients, while 27.50% of the patients attained the recommended level of serum cholesterol. Likewise, ADA recommended goal for blood pressure and LDL was achieved by13.02% and 12.16% patients respectively. Conclusions: The study showed that adherence of healthcare professionals to ADA guidelines was suboptimal. Moreover, insufficient documentation of medical records reflected inadequate care of patients with type 2 diabetes.
This work is performed to study the effect of adsorption of various first row adatoms (such as Be, C, F, Li and O) on (8, 0) zigzag boron nitride nanotubes (BNNTs) on their structural, electronic and magnetic properties. These calculations are based on density functional theory using pseudopotentials technique. For this purpose, five different sites namely axial, hexagonal, zigzag, on top of N and/or B (which are the most preferred available sites for adatoms on (8, 0) BNNTs) were utilized. The energetically stable sites for each of the first-row adatoms are found to be different because of their different electronic configurations caused by the charge transfer/ rearrangements between s-p or p-p orbitals. The binding energies of all adatoms on (8, 0) BNNTs have been calculated through structural optimization process after adsorbing these five adatoms at the above said sites on the BNNTs and are found to be in the energy range from −2.04 to 2.96 eV. It is further elaborated that F, Be and C adatoms on (8, 0) BNNTs show strong induced magnetization at specific localized sites depending upon the nature of adatom, whereas weak magnetization is noticed for Li and O adatoms on the BNNTs. Such localized induced magnetization could be associated with the hybridization of s-p or p-p orbitals of adatoms and B and/or N atoms.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.